Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study
- PMID: 22537422
- PMCID: PMC3582350
- DOI: 10.1053/j.ajkd.2012.03.011
Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study
Abstract
Background: Serum cystatin C level has been shown to have a stronger association with clinical outcomes than serum creatinine level. However, little is known about the combined association of cystatin C-based estimated glomerular filtration rate (eGFR(cys)) and albuminuria with clinical outcomes, particularly at levels lower than current chronic kidney disease (CKD) cutoffs.
Study design: Prospective cohort.
Setting & participants: 10,403 ARIC (Atherosclerosis Risk in Communities) Study participants followed up for a median of 10.2 years.
Predictor: eGFR(cys), albuminuria.
Outcomes: Mortality, coronary heart disease (CHD), and heart failure, as well as a composite of any of these separate outcomes.
Results: Both decreased eGFR(cys) and albuminuria were associated independently with the composite outcome, as well as mortality, CHD, and heart failure. Although eGFR(cys) of 75-89 mL/min/1.73 m(2) in the absence of albuminuria (albumin-creatinine ratio [ACR] <10 mg/g) or albuminuria with ACR of 10-29 mg/g with normal eGFR(cys) (90-104 mL/min/1.73 m(2)) was not associated significantly with any outcome compared with eGFR(cys) of 90-104 mL/min/1.73 m(2) and ACR <10 mg/g, the risk of each outcome was significantly higher in those with both eGFR(cys) of 75-89 mL/min/1.73 m(2) and ACR of 10-29 mg/g (for mortality, HR of 1.4 [95% CI, 1.1-2.0]; for CHD, HR of 1.9 [95% CI, 1.4-2.6]; for heart failure, HR of 1.8 [95% CI, 1.2-2.7]). Combining the 2 markers improved risk classification for all outcomes (P < 0.001), even in those without overt CKD.
Limitations: Only one measurement of cystatin C.
Conclusions: Mildly decreased eGFR(cys) and mild albuminuria independently contributed to the risk of mortality, CHD, and heart failure. Even minimally decreased eGFR(cys) (75-89 mL/min/1.73 m(2)) is associated with increased risk in the presence of mild albuminuria. Combining the 2 markers is useful for improved risk stratification even in those without clinical CKD.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Figures

Comment in
-
Cystatin C, creatinine, and albuminuria: bringing risk into 3 dimensions.Am J Kidney Dis. 2012 Aug;60(2):176-8. doi: 10.1053/j.ajkd.2012.05.003. Am J Kidney Dis. 2012. PMID: 22805517 Free PMC article. No abstract available.
References
-
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult us population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12. - PubMed
-
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047. - PubMed
-
- Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:1307–1315. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- T32 HL007024/HL/NHLBI NIH HHS/United States
- HSN268201100006C/PHS HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- 5T32HL007024/HL/NHLBI NIH HHS/United States
- R01 DK076770/DK/NIDDK NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials